Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections
The investigators hypothesis:
Presence of anti-GGT (antibody against GGT) indicates H. pylori infection.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Subjects will be requested to provide 1-5g of their solid/semi-solid stool sample, to be collected within 24 hours prior to their scheduled visit for urea breath test. Patients should not have been treated for H. pylori prior to stool collection. Stool samples will be tested using ELISA for the presence of the H. pylori GGT antigen using monoclonal antibodies against GGT. Stool samples will also be tested for the presence of H. pylori DNA using PCR and Western blot analysis respectively.
Presence of the GGT antigen in stool will be compared between H. pylori-positive and H. pylori-negative patients. Rapid urease test results will be used as the gold standard of H. pylori diagnosis. The sensitivity and specificity of the stool antigen test will be established.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lee Guan Lim
- Phone Number: 67795555
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- Nuhs Umc/Udc
-
Contact:
- Lee Guan Lim
- Phone Number: 67795555
-
Sub-Investigator:
- Lee Guan Lim
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The subject is greater than 21 years of age.
- The subject must have personally signed and dated the patient informed consent form indicating that he/she has been informed of all pertinent aspects of the study.
- The subject must be willing and able to comply with scheduled visits and other study procedures.
Exclusion Criteria:
- Subjects who have been taking antibiotics over the past 1 month will be excluded from study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Helicobactor Pylori Infection
Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects.
Rapid urease test result from the respective patients will be used as the golden standard.
Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stool anti-GGT for the diagnosis of Helicobactor Pylori Infection
Time Frame: 1 month after stool samples collected
|
1-5g of stool samples will also be collected from patients recruited to this study, in a preliminary investigation to determine the sensitivity and specificity of a stool H.pylori antigen test. Rapid urese test is the gold standard. |
1 month after stool samples collected
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lee Guan Lim, NUHS
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2011/00113
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HELICOBACTER PYLORI INFECTIONS
-
NCT07293910RecruitingHELICOBACTER PYLORI INFECTIONS | Helicobacter Infection | Helicobacter Pylori Gastrointestinal Tract Infection | Helicobacter Pylori Infected Patients
-
NCT07533422Not yet recruitingHELICOBACTER PYLORI INFECTIONS | Rescue Therapy for Helicobacter Pylori
-
NCT06751121CompletedHelicobacter Pylori Infection | Helicobacter Pylori Infected Subjects | Helicobacter Pylori Infected Patients
-
NCT07179159Recruiting
-
NCT07455448CompletedHELICOBACTER PYLORI INFECTIONS
-
NCT07246681Active, not recruitingHELICOBACTER PYLORI INFECTIONS
-
NCT07142798Enrolling by invitation
-
NCT07606833Not yet recruiting
-
NCT07574983Not yet recruitingHELICOBACTER PYLORI INFECTIONS
-
NCT07275827Not yet recruiting